CPAI - ETF AI Analysis
Top Page
Counterpoint Quantitative Equity ETF (CPAI)
CPAI, the Counterpoint Quantitative Equity ETF, earns a solid overall rating driven mainly by strong, AI-focused chip and hardware names like Micron and Marvell, which benefit from robust revenue growth, positive earnings calls, and strategic positioning in AI and data centers. ON Semiconductor and Astera Labs also support the fund’s quality through healthy cash flow and expansion, though high valuations and some profitability challenges across several holdings, including names like BlackBerry and 10x Genomics, temper the rating. The main risk is that many top positions share similar issues around rich valuations and uneven profitability, which could increase volatility if market sentiment toward these growth-oriented tech names weakens.
CPAI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 509.89M
- Region
- North America
- Expense Ratio
- 0.75%
- Beta
- 1.01
- Issuer
- Counterpoint
- Inception Date
- Nov 28, 2023
- Dividend Yield
- 0.68%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
CPAI Summary
The Counterpoint Quantitative Equity ETF (CPAI) is a U.S. stock fund that uses a data-driven strategy instead of tracking a set index. It aims to cover the total U.S. market, mixing different sizes and styles of companies, from growth to value. Its holdings span many sectors, with a big focus on technology and health care, and include well-known names like Apple and ConocoPhillips. Someone might invest in CPAI to get broad diversification and long-term growth in a single fund. A key risk is that it is heavily invested in U.S. stocks, so its value can rise and fall sharply with the overall stock market.
How much will it cost me?
The Counterpoint Quantitative Equity ETF (CPAI) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, using a quantitative approach to select stocks rather than simply tracking an index.
What would affect this ETF?
The Counterpoint Quantitative Equity ETF (CPAI), with its focus on the U.S. market and diverse sector exposure, could benefit from strong growth in technology and healthcare sectors, driven by innovation and increased demand. However, it may face challenges from rising interest rates or economic slowdowns, which could negatively impact consumer spending and cyclical industries. Regulatory changes or geopolitical tensions affecting North America could also influence the ETF's performance.
CPAI Top 10 Holdings
CPAI is leaning hard into U.S. tech and semiconductor names, with Micron and Marvell acting as key engines thanks to their steady, AI-fueled momentum. Intel and ON Semiconductor are more mixed, occasionally losing grip as profitability and growth questions surface, which can tug on returns. 10x Genomics has been rising lately but remains a bit of a wild card given uneven fundamentals. PayPal adds a splash of fintech that’s still trying to regain its stride. Overall, this is a U.S.-centric, chip-heavy fund where a handful of tech names set the tone.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 P | Everpure | 2.40% | $12.34M | $42.35B | 38.37% | 64Neutral |
 BOX | Box | 2.38% | $12.22M | $5.55B | 24.00% | 65Neutral |
 ETSY | Etsy | 2.33% | $11.98M | $7.83B | 21.00% | 57Neutral |
 MCK | McKesson | 2.30% | $11.80M | $117.81B | 28.55% | 62Neutral |
 CLF | Cleveland-Cliffs | 2.25% | $11.54M | $8.04B | 5.86% | 54Neutral |
 CAH | Cardinal Health | 2.23% | $11.48M | $58.50B | 61.53% | 66Neutral |
 MPC | Marathon Petroleum | 2.22% | $11.41M | $133.02B | 156.78% | 66Neutral |
 AR | Antero Resources | 2.21% | $11.36M | $11.94B | 26.15% | 67Neutral |
 NOG | Northern Oil And Gas | 2.20% | $11.32M | $2.96B | 28.53% | 72Outperform |
 SMPL | Simply Good Foods | 2.18% | $11.21M | $973.07M | -55.21% | 63Neutral |
CPAI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CPAI, the sentiment is Neutral. The current price of 52.49 is below the 20-day moving average (MA) of 52.60, above the 50-day MA of 52.35, and above the 200-day MA of 47.88, indicating a neutral trend. The MACD of 0.18 indicates Positive momentum. The RSI at 45.73 is Neutral, neither overbought nor oversold. The STOCH value of 21.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CPAI.
CPAI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| CPAI | $52.49 | $56.00(6.69% Upside) | $509.89M | 0.75% | 64Neutral |
 SEUS | $25.82 | $30.72(18.97% Upside) | $936.19M | 0.30% | 73Outperform |
 BGDV | $30.89 | $36.91(19.48% Upside) | $859.89M | 0.45% | 74Outperform |
 AAUB | $50.71 | $61.98(22.23% Upside) | $971.65M | 0.10% | 69Neutral |
 AVTM | $54.56 | $64.29(17.84% Upside) | $777.23M | 0.22% | 60Neutral |
 XCHG | $27.52 | $33.08(20.20% Upside) | $713.97M | 0.50% | 70Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CPAI | Counterpoint Quantitative Equity ETF | 52.49 | 13.74 | 35.47% | |
| SEUS | SEI QiM U.S. Equity Factor Allocation Active ETF | 25.82 | 0.56 | 2.21% | |
| BGDV | Bahl & Gaynor Dividend ETF | 30.89 | 4.43 | 16.75% | |
| AAUB | Alpha Architect US Equity 4 ETF | 50.71 | 1.22 | 2.47% | |
| AVTM | Avantis Total Equity Markets ETF | 54.56 | 4.91 | 9.90% | |
| XCHG | AB US Equity ETF | 27.52 | 2.67 | 10.75% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.